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The testis determining protein, Sry, has functions outside of testis determination. Multiple Sry loci are found on the Y-
chromosome. Proteins from these loci have diﬀerential activity on promoters of renin-angiotensin system genes, possibly
contributing to elevation of blood pressure. Variation at amino acid 76 accounts for the majority of diﬀerential eﬀects by rat
proteins Sry1 and Sry3. Human SRY regulated rat promoters in the same manner as rat Sry, elevating Agt, Ren,a n dAce promoter
activity while downregulating Ace 2. Human SRY signiﬁcantly regulated human promoters of AGT, REN, ACE2, AT2, and MAS
compared to control levels, elevating AGT and REN promoter activity while decreasing ACE2, AT2, and MAS. While the eﬀect of
human SRY on individual genes is often modest, we show that many diﬀerent genes participating in the renin-angiotensin system
can be aﬀected by SRY, apparently in coordinated fashion, to produce more Ang II and less Ang-(1–7).
1.Introduction
Many genes on the Y chromosome that are expressed in
tissues not involved in testis formation could contribute
to sex diﬀerences in blood pressure and other disease
phenotypes. Sry is believed to have evolved from the X
chromosomegeneSox3duringtheprocessofY-chromosome
formation in therian mammals [1]. Since Sox3 has functions
other than testis determination [2], Sry may also have
additional functions outside testis determination. Sry and
other Sox proteins are architectural transcription factors that
bind to the minor groove of DNA, changing gene regulation
through inducing a bend in the DNA [3].
The spontaneously hypertensive rat (SHR) has at least
seven expressed Sry loci whereas the normotensive Wistar
Kyoto (WKY) rat has at least six [4], lacking Sry3.S r y
transcripts have been observed in adult rat tissues consistent
with blood pressure regulation [5], and one or more of
the Sry loci play a role in the development of hypertension
in SHR [6]. Many rodent species have multiple Sry loci,
while human and mouse have only one known locus.
Sry proteins in human, rat, and other placental mammals
have a homologous HMG box, hinge region, and bridge
domain, with little homology in the N and C terminal ends
(Figure 1(a)). The role of Sry regulation of blood pressure
in humans has not been studied directly. However, with the
high degree of conservation in the DNA-binding domain
betweenhumanandrat,functionsofSryseeninratarelikely
to translate into clinical relevance for human male blood
pressure regulation.
Of the rat Sry proteins we have examined, Sry3 proteins
have the largest eﬀect on promoters of the renin-angiotensin
system (RAS) genes [7]. Additionally, the Sry3 locus is found
only in SHR, making it a prime candidate for elevating2 International Journal of Hypertension
blood pressure. Sry1 [8]a n dS r y 3[ 9] proteins of rat have
been shown to elevate blood pressure in normotensive rats.
Delivery of Sry1 is known to regulate tyrosine hydroxylase
promoter activity in cultured cells [10] and in rats [9]. Two
amino acid diﬀerences are found between Sry1 and Sry3, a
histidine (Sry1) to glutamine (Sry3) at amino acid 38 and
a proline (Sry1) to threonine (Sry3) at amino acid 76 [4].
At these two amino acids, humans share one with each rat
Sry protein: proline at amino acid 131 is the same as amino
acid 76 of Sry1 and glutamine at amino acid 93 is the same
as amino acid 38 of Sry3. The aim of this study was to
identify the role of these two amino acid diﬀerences in rat,
and to address the role of human SRY on regulation of rat
and human RAS promoter constructs identifying possible
conserved functions of Sry in blood pressure regulation
across species.
2. Methods
2.1. Sry Modeling. Models for Sry1, Sry3 and hSRY proteins
were created with iTASSER [11]. Models that contained
a DNA-binding cleft with the best conﬁdence score were
selected. Manipulations and highlighting of structures were
performed with YASARA (http://www.yasara.org/). Models
weresuperposedtoDNAusingPDBstructure1j46[12].1j46
is a structure determined through NMR of the human SRY
HMG box bound to a fragment of DNA containing the SRY
binding element. To produce structure 1j46 P76T, proline
76 was swapped with a threonine using YASARA Structure.
Both 1j46 and 1j46 (P76T) were energy minimized with
AMBER03 force ﬁeld [13].
2.2. Cloning. Mutant Sry constructs were designed using
pEF-1 expression vectors containing rat Sry1 (EU984075),
Sry3 (EU984077), or human SRY (NM 003140) through
primer directed mutagenesis. Constructs are shown in
Table 1, identifying the amino acid found at 76 (131 of
human). Primers were phosphorylated with T4 polynu-
cleotide kinase (Fermentas) and used in PCR with Phusion
Hot Start Taq (Finnzymes). T4 DNA ligase (Fermentas) was
used for ligations. Following transformation into TAM-1
competent E. coli (Active Motif), clones were sequenced with
BigDyeTerminatorchemistryonABI3130xlgeneticanalyzer
(Applied Biosystems). Luciferase reporter vectors (pGL3)
for rat angiotensinogen (Agt), renin (Ren), angiotensin-I
convertingenzyme(Ace),andangiotensin-2convertingenzyme
(Ace2) were previously described [6]. Human promoters
of AGT, REN, ACE, ACE 2, MAS1 oncogene (MAS), and
angiotensinIIsubtype2receptor (AT2)wereclonedintopGL3
using primers and restriction enzymes listed in Table 2.
Because of the way the constructs were made and the way
the luciferase assays were carried out, the levels of induction
on these promoters can only be compared to the control for
each promoter. Levels of activity on one promoter cannot be
compared to those of another promoter construct.
2.3. Cotransfections. CHO-K1 cells (ATCC) were plated at
5 × 104 cells per well into 24 well plates (COSTAR) with
Table 1: Sry expression constructs of rat and human showing the
amino acid at 76 in rat or 131 in human.
Construct 76 (131)
Sry1 P
Sry1 P76T T
Sry3 T
Sry3 T76P P
hSRY P
hSRY P131T T
HAMs F12K media (Sigma) supplemented with 10% fetal
bovine serum (Atlanta Biologicals), 10mmol/L HEPES, and
30mmol/L sodium bicarbonate and cultured in 5% CO2
and 95% humidity. Twenty four hours after plating, cotrans-
fections were performed using 50ng pEF-1 eﬀector vector,
500ng pGL3 reporter vector, 500pg phRL-null Renilla
control vector, 2µL TurboFect (Fermentas), and serum-free
HAMs-F12K media to 100µL. After twenty four hours, cells
were lysed and light intensity measured with Dual-Luciferase
Reporter Assay System (Promega).
2.4. Statistics. Results for each promoter were analyzed with
JMP by comparing relative intensity to an empty pEF-1
c o n t r o lv e c t o ro rr e s p e c t i v en o n m u t a t e dv e c t o r .A l lA N O V A s
that showed signiﬁcance (P ≤ 0.05) were followed by
Students t-tests. For all luciferase assays n = 3–5, each n
represents an individual experiment of dual measurements
fromtwo duplicate wells, anderror barsare standard error of
the mean (SEM) and ∗P ≤ 0.05, ∗∗P ≤ 0.01, ∗∗∗P ≤ 0.001.
3. Results
Models of variations at amino acids 38 and 76 previously
described were created to verify whether the variation could
potentially alter DNA interaction. This was determined by
either modeling the protein backbone independent of DNA
interaction with iTASSER or swapping amino acids in the
known hSRY structure (1j46) of Sry-DNA interaction. When
Sry is interacting with DNA, amino acid 38 (found in the
HMG box) is found on the opposite side of the DNA
interaction of the HMG box. Therefore, it does not appear
to contribute to DNA interaction. Amino acid 76 of rat Sry
(131 of human) is in the hinge domain (Figure 1(b) red) and
interactswithDNA.Aprolineataminoacid76interactswith
the DNA minor groove base pairs in a non-DNA sequence-
speciﬁc manner [12]. Models of Sry3, containing a threonine
at amino acid 76, show an altered protein backbone, which
would change the interaction of amino acid 76 from the
minor groove to the phosphate backbone of DNA (data not
shown).
Exchanging the proline of hSRY 1j46 (Figure 1(c))f o ra
threonine (Figure 1(d)) and energy minimizing the protein
bound to DNA led to the same shift in DNA interaction
as seen with modeling approaches. Bond distances between
the alpha carbon (CA, atom one) of either the prolineInternational Journal of Hypertension 3
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Rat Sry
Human Sry 76
131
N-terminus
HMG box
Bridge domain
C-
Hinge domain
terminus
(a)
DNA
Bridge
Hinge
HMG box
DN
Bridge
Hinge
HMG box
(b)
DC 107
DC 105
DA 126
DG 127
Atom 1
CA Pro76
CA Pro76
CA Pro76
CA Pro76
Atom 2
DC 107
DG 127
DA 126
DC 105
5.95
7.776
7.877
10.507
1J46
Pro 76
Distance (˚ A)
(c)
Thr 76
Atom 2
DC 107
DG 127
DA 126
DC 105
4.737
8.876
8.822
12.774
DC 107
DC 105
DA 126
DG 127
CA Thr 76
CA Thr 76
CA Thr 76
CA Thr 76
Atom 1 Distance (˚ A)
1J46 (P76T)
(d)
Figure 1: Modeling Sry variations of Sry1, Sry3, and hSRY. (a) Schematic of the rat Sry and human SRY proteins with amino acid 76 of
rat (131 of human) shown. In red is the N-terminus, black the HMG box, blue the hinge domain, green the bridge domain, and orange the
C-terminus. (b) Amino acid 76 (red) can be seen to interact with DNA (cyan) on modeled rat Sry1. (c) 1j46 (human SRY bound to DNA)
was energy-minimized and the distances of the carbon alpha of the proline, amino acid at 76 (131), were measured from four diﬀerent
phosphates of DNA (DC 105, DC 107, DG 127, and DA 126). (d) 1j46 (P76T), in which the proline was substituted with a threonine, was
energy-minimized and distance-measured.
(Figure 1(c)) or threonine (Figure 1(d))w i t hf o u rd i ﬀerent
phosphates of DNA bases (atom two) conﬁrm the shift
relative to DNA. The CA of threonine (Figure 1(d))i s
shifted closer (by 1.213 ˚ A) to the phosphate of DC 107
(4.737 ˚ A compared to 5.950 ˚ A), while farther from DG127
(by 1.100 ˚ A), DA126 (by 0.945 ˚ A), and DC105 (by 2.267 ˚ A)
compared to proline (Figure 1(c)). This suggests the CA is
shifting out of the minor groove and closer to the phosphate
backbone when changed to threonine.
Mutation of amino acid 76 from proline to threonine in
Sry1 (Sry1 P76T) signiﬁcantly increased promoter activity
from Ren, Ace and Ace2 relative to nonmutated Sry1 (P ≤
0.05, Figure 2(a)). Mutation of Sry3 at amino 76 from
threonine to proline (Sry3 T76P) decreased Agt, Ace,a n d
Ace2 promoter activity (P ≤ 0.05, Figure 2(b)). Mutagenesis
of rat amino acid 38 (93 of human) showed no signiﬁcant
eﬀect on activity of any promoters constructs tested (data
not shown). Cotransfecting hSRY expression constructs with
rat RAS promoters signiﬁcantly regulated each construct in
the same manner as rat Sry [7]b u tw i t hd i ﬀerent relative
intensities (Figure 3). Mutation of hSRY at amino acid 131
from proline to threonine (hSRY P131T) caused a signiﬁcant
increase in both Ren and Ace2 promoter activities.
Human SRY signiﬁcantly regulated the human promot-
ers of AGT (P ≤ 0.001), REN (P ≤ 0.001), ACE2 (P ≤
0.001), AT2 (P ≤ 0.001), and MAS (P ≤ 0.001) compared to
control levels (Figure 4), elevating AGT and REN promoter
activity while decreasing ACE2, AT2,a n dMAS.M u t a t i o n
P131T caused an alteration in hSRY regulation on all these
promoters. Sry3 signiﬁcantly regulated AGT, ACE2, AT2,a n d
MAS. The human ACE promoter construct used in these
studies was not regulated by hSRY or Sry3.International Journal of Hypertension 5
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Figure2:Variationataminoacid76ofratSryproteinseﬀectsonrat
RAS gene promoters. Amino acid variation between Sry1 and Sry3
results in diﬀerential activity on promoters of the RAS with Sry1
P76T (a) and Sry3 T76P (b). (a) Sry1 P76T signiﬁcantly increased
activityonRen, Ace,andAce2.(b)Sry3T76Psigniﬁcantlydecreased
activity on Agt, Ace,a n dAce2. Asterisks indicate signiﬁcance from
respective nonmutant Sry.
∗P ≤ 0.05,
∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001.
Blue bars are the control pEF-1 vector and black bars represent
proteins with a proline at amino acid 76.
4. Discussion
Hypertension is a complex disease, and distinguishing
among a myriad of genetic and environmental factors is
diﬃcult.Inhumansandotheranimalmodels,bloodpressure
is higher in males than premenopausal females [14, 15]. This
may be due to a genetic component that is male speciﬁc
such as the Y-chromosome gene Sry. Accumulating evidence
suggests that Sry has functions not directly related to testis
determination[16].Thisstudy,aswellasothersfromourlab,
suggeststhatSryisacontributortoincreasingbloodpressure
in SHR. Here we show that this Sry-mediated increase in
blood pressure may translate into humans since both rat and
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Figure 3: Human SRY regulation of rat RAS gene promoters.
Human SRY (black) increases promoter activity of rat Agt, Ren,
and Ace while decreasing Ace2 as previously seen with Sry1 and
Sry3. Mutations to the proline 131 of hSRY to threonine (gray)
signiﬁcantly increased activity in Ren and Ace2 while they had a
trend in decreasing activity on Agt and Ace. Signiﬁcance of hSRY
is based on comparison to the control vector (blue) or for hSRY
P131T to the hSRY values.
∗P ≤ 0.05,
∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001.
human proteins seem to function similarly. Sry activation of
theRASgenepromoters[7],combinedwiththeeﬀectsofSry
on the sympathetic nervous system [8, 10], could contribute
to sex diﬀerences in hypertension.
In SHR males, androgens have been shown to increase
plasma Ren, renal Agt, and hepatic Agt [17]. Sry is known to
interact with the androgen receptor (AR) and aﬀect AR gene
regulation [18]. It is thus probable that Sry and androgens
coregulate the RAS and other genes.
In this study we have identiﬁed and characterized the
amino acid in the rat Sry1 and Sry3 proteins that cause their
diﬀerential eﬀects on regulation of RAS gene promoters. Rat
amino acid 38 (93 of human) has no published function
or natural variation resulting in phenotypic change. Known
structures of Sry and the models created here show that this
amino acid is not likely to contribute to DNA interactions,
and promoter activity assays support this.
The majority of variation of rat Sry protein diﬀerences
on the RAS could be explained from results of mutations
at amino acid 76 of rat (131 of human). In humans, a
mutation of the proline to an arginine at amino acid 131
was present in an individual with sex reversal [19], showing
signiﬁcance of this amino acid. Modeling Sry1, Sry3, and
hSRY suggests that the proline and threonine diﬀerences
could account for altered interactions with DNA. NMR
experiments showed that the proline of Sry interacts with6 International Journal of Hypertension
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Figure 4: Human SRY regulation of the human RAS gene promoters. Human SRY (hSRY, black) signiﬁcantly regulated human AGT, REN,
ACE 2, AT2,a n dMAS promoters. Signiﬁcance of hSRY is based on comparison to the control vector (blue). The mutation at amino acid 131
(hSRYP131T,gray)signiﬁcantlydiminishedfunctioninAGT, REN,ACE 2, AT2,andMASconstructsrelativetohSRY.Sry3(red)signiﬁcantly
regulated AGT, ACE2, AT2,a n dMAS compared to control (blue).
∗P ≤ 0.05,
∗∗P ≤ 0.01,
∗∗∗P ≤ 0.001.
the base pairs of the minor groove and the sugars of the
DNA backbone [12]. Modeling variation through prediction
of structure with iTASSER or changing structure 1j46 both
showed a shift in the threonine of Sry3 to be more likely to
interact with the phosphate backbone of DNA. The hinge
region serves as a kinetic clamp for Sry-DNA interaction
[20]. The hydrophobicity of the proline, at position 76/131,
allows this residue to ﬁt into the DNA minor groove,
reducing the solvent accessible surface compared to the
threonine (data not shown) and improving the stability
of this Sry-DNA interaction. Alternatively, the presence
of threonine may alter the solvent accessible surface and
change the thermodynamics and kinetics of the Sry-DNA
complex by potentially reducing kinetic clamp ability in Sry.
In general, hSRY behaves similar to the rat Sry proteins
with the exception that a change to threonine at amino
acid 131 (correlating to rat amino acid 76) alters gene
regulation from nonmutated much greater than in the rat.
We believe that variations in the divergent bridge domain
between rat and human may stabilize rat proteins containing
a threonine, for example Sry3, more strongly than human
SRY.
Although CHO cells are not normally used in analysis
of the RAS, they provide us with several beneﬁts. Co-
transfectioneﬃciencyisveryhighinCHOcells.Alsotheyare
eﬃcientforrecombinantproteinexpression.SinceCHOcells
are from the ovary and lack the Y chromosome, there is no
endogenous Sry expression. There is an ovarian tissue RAS,
with ovary tissue or CHO cells shown to express prorenin,
Ren, Ang, Ace, Ace 2, Ang II, and Ang II receptors [21–
24]. Our promoter constructs contain only the proximal
promoter region and a few hundred bases upstream, thus
they cannot tell us if Sry activates RAS promoters diﬀerently
in vitro or in vivo. Electroporation of Sry3 into the kidney
increased Ang II and plasma Ren activity [9], which we
believe is likely through the gene regulation we see in this
study and thus provides in vivo gene support of the validity
o fo u rp r o m o t e ra c t i v i t ya s s a y s .International Journal of Hypertension 7
We have long been interested in determining how human
and mouse, with only a single Sry gene, can potentially
performallthefunctionsofSry encompassedbythemultiple
copies in rat. Human SRY behaves in a manner similar
to both Sry1 and Sry3 in regulation of rat Agt, Ren, Ace,
and Ace2 promoters. Promoters of the human RAS showed
similar responses to hSRY and Sry3, with hSRY P131T losing
regulation. The human ACE promoter we used showed no
signiﬁcant change in activity with hSRY, and after analysis
of Sry-binding sites using Genomatix MatInspector we could
not identify any Sry-binding elements in the ACE promoter
used in our experiments. Several potential Sry-binding
s i t e sa r ep r e s e n ti nl o n g e rp r o m o t e rs e q u e n c e so fh u m a n
ACE. Additional experiments using longer ACE promoter
sequences are necessary to address this issue, which will
likely yield results similar to the rat Ace promoter. All
other promoters used contained Sry and AP1-binding sites
requiredforcis-Sryactivation.Inapreviousstudyweshowed
that Sry acts primarily through the AP1 binding site for
activation of the tyrosine hydroxylase promoter [10].
The data presented here suggest that human and rat
Sry proteins and their genome targets (either cis or trans)
regulating the RAS have remained functionally conserved.
RegulationoftheRASbySry appearstofavortheproduction
of Ang II, possibly reducing Ang-(1–7) and MAS levels [7].
MAS is known to be the receptor of Ang-(1–7) which can
counter the eﬀects of Ang II [25], thus the gene regulation
by Sry suggests not only increasing the Ang II signaling,
which has been shown in vivo, but also decreasing the
counter pathway of Ang-(1–7). In addition, AT2 receptor
promoter activity was decreased by human SRY, supporting
its repressing eﬀects on RAS components that oppose Ang
II actions. Despite past uncertainty about the role of AT2
receptor, recent studies have conﬁrmed AT2 receptor as a
vasodilator mediator [26]. Human SRY likely plays a role
similar to that of rat Sry in the regulation of blood pressure.
It will be interesting to explore further the role this may serve
in human hypertensive disease phenotypes.
5. Conclusions
Variations of amino acid 76 in rat (131 in human) led to
diﬀerential regulation of rat RAS gene promoters. This study
is the ﬁrst to show that hSRY can regulate RAS promoters
in the same pattern as rat Sry. In addition, by analyzing
the human promoters of RAS, we show that potential cis-
or trans-binding sites for Sry are conserved, indicating a
c o n s e r v e dr o l eo fS r yi nh u m a nb l o o dp r e s s u r e .
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